Literature DB >> 26692454

Effect of drug resistance on negative conversion of sputum culture in patients with pulmonary tuberculosis.

Joohae Kim1, Nakwon Kwak1, Ha Youn Lee1, Taek Soo Kim2, Chang-Ki Kim3, Sung Koo Han1, Jae-Joon Yim4.   

Abstract

OBJECTIVE: Negative conversion of sputum culture is a useful marker for predicting treatment outcome and relapse of pulmonary tuberculosis (TB). The effect of drug resistance on negative conversion of sputum culture with treatment was evaluated in this study.
METHODS: A total of 535 patients with culture-proven pulmonary TB were classified into three groups: drug-susceptible (DS), other drug-resistant (ODR), and multidrug-resistant/extensively drug-resistant (MDR/XDR). Rates of conversion of sputum culture at 4, 8, and 12 weeks were compared.
RESULTS: At 4 weeks of treatment, the conversion rate in the DS group (52.7%) was higher than that in the ODR group (30.8%, p=0.003), but was not different compared with the MDR group (45.7%, p=0.427). At 8 weeks, the conversion rate in the DS group (76.3%) was higher than that in the ODR (63.5%, p=0.042) and MDR groups (60.0%, p=0.031). At 12 weeks, the conversion rate in the DS group (85.9%) tended to be higher than that in the MDR group (74.3%, p=0.062), but was not different from that in the ODR group (84.6%, p=0.796).
CONCLUSION: The pattern of resistance to anti-TB drugs affects culture conversion rates in the early phase of treatment and also prolongs the time to culture conversion.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Conversion time; Drug resistance; Tuberculosis

Mesh:

Substances:

Year:  2015        PMID: 26692454     DOI: 10.1016/j.ijid.2015.11.018

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  6 in total

1.  Predictors of time to sputum culture conversion in multi-drug-resistant tuberculosis and extensively drug-resistant tuberculosis in patients at Tshepong-Klerksdorp Hospital.

Authors:  Relebohile Ncha; Ebrahim Variava; Kennedy Otwombe; Mary Kawonga; Neil A Martinson
Journal:  S Afr J Infect Dis       Date:  2019-08-26

2.  Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial.

Authors:  Ji Yeon Lee; Deog Kyeom Kim; Jung-Kyu Lee; Ho Il Yoon; Ina Jeong; Eunyoung Heo; Young Sik Park; Jae Ho Lee; Sung Soo Park; Sang-Min Lee; Chang-Hoon Lee; Jinwoo Lee; Sun Mi Choi; Jong Sun Park; Joon-Sung Joh; Young-Jae Cho; Yeon Joo Lee; Se Joong Kim; Young Ran Hwang; Hyeonjeong Kim; Jongeun Ki; Hyungsook Choi; Jiyeon Han; Heejung Ahn; Seokyung Hahn; Jae-Joon Yim
Journal:  Trials       Date:  2017-02-13       Impact factor: 2.279

3.  Time to sputum smear and culture conversions in multidrug resistant tuberculosis at University of Gondar Hospital, Northwest Ethiopia.

Authors:  Agumas Shibabaw; Baye Gelaw; Shu-Hua Wang; Belay Tessema
Journal:  PLoS One       Date:  2018-06-26       Impact factor: 3.240

4.  Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: A retrospective cohort study.

Authors:  Arto Yuwono Soeroto; Chica Pratiwi; Prayudi Santoso; Bony Wiem Lestari
Journal:  PLoS One       Date:  2021-02-08       Impact factor: 3.240

5.  Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial.

Authors:  Nakwon Kwak; Doosoo Jeon; Youngmok Park; Young Ae Kang; Kyung Jong Kim; Young Ran Kim; Byoung Soo Kwon; Yong-Soo Kwon; Hyung-Jun Kim; Jae Ho Lee; Ji Yeon Lee; Jung-Kyu Lee; Jeongha Mok; Minkyoung Cheon; Jiwon Park; Seokyung Hahn; Jae-Joon Yim
Journal:  Trials       Date:  2022-08-17       Impact factor: 2.728

6.  Randomized Trial of Metformin With Anti-Tuberculosis Drugs for Early Sputum Conversion in Adults With Pulmonary Tuberculosis.

Authors:  Chandrasekaran Padmapriydarsini; Megha Mamulwar; Anant Mohan; Prema Shanmugam; N S Gomathy; Aarti Mane; Urvashi B Singh; Nathella Pavankumar; Abhijeet Kadam; Hemanth Kumar; Chandra Suresh; Devaraju Reddy; Poornaganga Devi; P M Ramesh; Lakshmanan Sekar; Shaheed Jawahar; R K Shandil; Manjula Singh; Jaykumar Menon; Randeep Guleria
Journal:  Clin Infect Dis       Date:  2022-08-31       Impact factor: 20.999

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.